Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Stephen Daniel Wiviott, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Oyama K, Raz I, Cahn A, Goodrich EL, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2022 Sep 01; 7(9):914-923. PMID: 35857296; PMCID: PMC9301591.
    Citations:    Fields:    
  2. Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Špinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J. 2022 08 14; 43(31):2958-2967. PMID: 34427295.
    Citations: 1     Fields:    
  3. Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Aylward P, Dalby AJ, Dellborg M, Dimulescu D, Nicolau JC, Oude Ophuis AJM, Cahn A, Mosenzon O, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 2022 05 24; 145(21):1581-1591. PMID: 35510542.
    Citations:    Fields:    Translation:Humans
  4. Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, Langkilde AM, Mahaffey KW, McGuire DK, Neal B, Perkovic V, Pong A, Sabatine MS, Raz I, Toyama T, Wanner C, Wheeler DC, Wiviott SD, Zinman B, Heerspink HJL. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation. 2022 05 10; 145(19):1460-1470. PMID: 35394821.
    Citations: 1     Fields:    Translation:Humans
  5. Sammons E, Hopewell JC, Chen F, Stevens W, Wallendszus K, Valdes-Marquez E, Dayanandan R, Knott C, Murphy K, Wincott E, Baxter A, Goodenough R, Lay M, Hill M, Macdonnell S, Fabbri G, Lucci D, Fajardo-Moser M, Brenner S, Hao D, Zhang H, Liu J, Wuhan B, Mosegaard S, Herrington W, Wanner C, Angermann C, Ertl G, Maggioni A, Barter P, Mihaylova B, Mitchel Y, Blaustein R, Goto S, Tobert J, DeLucca P, Chen Y, Chen Z, Gray A, Haynes R, Armitage J, Baigent C, Wiviott S, Cannon C, Braunwald E, Collins R, Bowman L, Landray M. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022 04 06; 43(14):1416-1424. PMID: 34910136; PMCID: PMC8986460.
    Citations: 1     Fields:    Translation:Humans
  6. Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, Kuder JF, Park JG, Murphy SA, Verma S, Wojakowski W, Terra SG, Sabatine MS, Wiviott SD. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022 05 03; 145(18):1377-1386. PMID: 35369705; PMCID: PMC9047643.
    Citations: 1     Fields:    Translation:Humans
  7. Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Raz I. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 2022 04 01; 45(4):938-946. PMID: 35015847.
    Citations: 2     Fields:    Translation:Humans
  8. Kolkailah AA, Wiviott SD, Raz I, Murphy SA, Mosenzon O, Bhatt DL, Leiter LA, Wilding JPH, Gause-Nilsson I, Sabatine MS, McGuire DK. Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care. 2022 02 01; 45(2):e27-e29. PMID: 35020832; PMCID: PMC8914433.
    Citations: 1     Fields:    Translation:Humans
  9. Bonaca MP, Antman EM, Cunningham JW, Wiviott SD, Murphy SA, Halperin JL, Weitz JI, Grosso MA, Lanz HJ, Braunwald E, Giugliano RP, Ruff CT. Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. Eur Heart J Cardiovasc Pharmacother. 2021 Dec 28. PMID: 34962979.
    Citations:    Fields:    
  10. Paruchuri K, Finneran P, Marston NA, Healy EW, Andreo J, Lynch R, Blood AJ, Jones-O'Connor M, Lander B, Kelly N, Vivaldi MT, Traynor K, Wiviott S, Natarajan P. Outcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention. EBioMedicine. 2021 Oct; 72:103593. PMID: 34657825; PMCID: PMC8577401.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  11. Wiviott SD, Giugliano RP, Sabatine MS. Myocardial Infarction and Evolocumab-Reply. JAMA Cardiol. 2021 10 01; 6(10):1222-1223. PMID: 34160553.
    Citations:    Fields:    Translation:Humans
  12. Berg DD, Wiviott SD, Scirica BM, Zelniker TA, Goodrich EL, Jarolim P, Mosenzon O, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Langkilde AM, Raz I, Braunwald E, Sabatine MS, Morrow DA. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 2021 11; 44(11):2573-2581. PMID: 34535469; PMCID: PMC8546278.
    Citations: 1     Fields:    Translation:Humans
  13. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 08; 44(8):1805-1815. PMID: 34233928.
    Citations: 7     Fields:    Translation:Humans
  14. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021 07 01; 6(7):801-810. PMID: 33851953; PMCID: PMC8047725.
    Citations: 5     Fields:    Translation:Humans
  15. Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SD. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care. 2021 05; 44(5):1159-1167. PMID: 33653824.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  16. O'Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, Šmahelová A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SD. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia. 2021 06; 64(6):1226-1234. PMID: 33611623.
    Citations: 2     Fields:    Translation:Humans
  17. Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O'Donoghue ML. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695. PMID: 33587654; PMCID: PMC7894618.
    Citations: 5     Fields:    Translation:Humans
  18. Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PG. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Arch Cardiovasc Dis. 2021 Mar; 114(3):187-196. PMID: 33518473.
    Citations:    Fields:    Translation:Humans
  19. Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack C, Petrauskiene B, Henry P, Dorobantu M, French WJ, Wiviott SD, Sabatine MS, Mehta SR, Steg PG. Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. Circ Cardiovasc Interv. 2021 01; 14(1):e009759. PMID: 33430604.
    Citations: 1     Fields:    Translation:Humans
  20. Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Bode C, Lewis BS, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Wiviott SD. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2021 06; 23(6):1026-1036. PMID: 33269486.
    Citations: 7     Fields:    Translation:Humans
  21. Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD, Braunwald E, Sabatine MS, Morrow DA. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol. 2020 11 01; 5(11):1255-1262. PMID: 32756916.
    Citations: 4     Fields:    Translation:Humans
  22. Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG. Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20. PMID: 33609103.
    Citations:    Fields:    
  23. Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG. Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20; 2048872619896205. PMID: 33081496.
    Citations: 1     Fields:    
  24. Xu H, Yang Y, Wang C, Yang J, Li W, Zhang X, Ye Y, Dong Q, Fu R, Sun H, Yan X, Gao X, Wang Y, Jia X, Sun Y, Wu Y, Zhang J, Zhao W, Sabatine MS, Wiviott SD. Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China. JAMA Netw Open. 2020 10 01; 3(10):e2021677. PMID: 33095249.
    Citations: 15     Fields:    Translation:Humans
  25. Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, McGuire DK, Litwak L, Kooy A, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Raz I. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021 01; 23(1):29-38. PMID: 32844557.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  26. Giugliano RP, Gencer B, Wiviott SD, Park JG, Fuchs CS, Goessling W, Musliner TA, Tershakovec AM, Blazing MA, Califf R, Cannon CP, Braunwald E. Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. JACC CardioOncol. 2020 Sep; 2(3):385-396. PMID: 34396246; PMCID: PMC8352126.
    Citations: 1     
  27. Zelniker TA, Raz I, Sabatine MS, Wiviott SD. Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". Circulation. 2020 09 08; 142(10):e129-e130. PMID: 32897752.
    Citations: 1     Fields:    Translation:Humans
  28. Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020 08 25; 142(8):734-747. PMID: 32795086.
    Citations: 9     Fields:    Translation:Humans
  29. Wiviott SD, Giugliano RP, Morrow DA, De Ferrari GM, Lewis BS, Huber K, Kuder JF, Murphy SA, Forni DM, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS. Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2020 07 01; 5(7):787-793. PMID: 32347885.
    Citations: 9     Fields:    Translation:Humans
  30. Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack CV, Wiviott SD, Rao SV, Jukema JW, Erglis A, Moccetti T, Elbez Y, Steg PG. Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. Int J Cardiol. 2020 Nov 01; 318:7-13. PMID: 32590084.
    Citations: 2     Fields:    Translation:Humans
  31. Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LA. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020 08; 22(8):1357-1368. PMID: 32239659.
    Citations: 10     Fields:    Translation:Humans
  32. Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SD. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020 03 17; 75(10):1095-1106. PMID: 32164882.
    Citations: 5     Fields:    Translation:Humans
  33. Bajaj HS, Raz I, Mosenzon O, Murphy SA, Rozenberg A, Yanuv I, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Sabatine MS, Wiviott SD, Cahn A. Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. Diabetes Obes Metab. 2020 07; 22(7):1122-1131. PMID: 32090404.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  34. Sun MT, Huang S, Wiviott SD, Antman EM, Roe MT, Ohman EM, Neely M, Wallentin L, Wong CX. Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. Am J Cardiol. 2020 04 15; 125(8):1280-1283. PMID: 32081368.
    Citations:    Fields:    Translation:Humans
  35. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott S, McMurray J, Granger C. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation. 2020 03 10; 141(10):843-862. PMID: 31992065.
    Citations: 13     Fields:    Translation:Humans
  36. Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020 04 14; 141(15):1227-1234. PMID: 31983236.
    Citations: 57     Fields:    Translation:Humans
  37. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2020 02; 43(2):468-475. PMID: 31843945.
    Citations: 11     Fields:    Translation:Humans
  38. Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O'Donoghue ML. Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022. PMID: 31865968.
    Citations: 10     Fields:    Translation:Humans
  39. McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019 12; 7(12):899-911. PMID: 31676222.
    Citations: 37     Fields:    Translation:Humans
  40. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 10 29; 74(17):2132-2146. PMID: 31648705.
    Citations: 27     Fields:    Translation:Humans
  41. Kato ET, Sabatine MS, Wiviott SD. Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus". Circulation. 2019 10 29; 140(18):e740-e741. PMID: 31657959.
    Citations:    Fields:    Translation:Humans
  42. Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F, Kuder JF, Mercuri MF, Lanz HJ, Braunwald E, Giugliano RP. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019 11 26; 140(22):1792-1801. PMID: 31597460.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  43. Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019 10 15; 140(16):1308-1317. PMID: 31530008; PMCID: PMC6791781.
    Citations: 33     Fields:    Translation:Humans
  44. Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 11 05; 140(19):1569-1577. PMID: 31474116; PMCID: PMC6829059.
    Citations: 23     Fields:    Translation:Humans
  45. Zelniker TA, Wiviott SD, Raz I, Sabatine MS. SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply. Lancet. 2019 08 17; 394(10198):560-561. PMID: 31423992.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  46. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology Circulation. 2019 07 02; 140(2):80-91. PMID: 31390169; PMCID: PMC6779326.
    Citations: 98     Fields:    Translation:Humans
  47. Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MS. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019 07 01; 4(7):613-619. PMID: 31116355; PMCID: PMC6537798.
    Citations: 16     Fields:    Translation:Humans
  48. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):606-617. PMID: 31196815.
    Citations: 155     Fields:    Translation:Humans
  49. Wiviott SD, Raz I, Sabatine MS. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2019 05 09; 380(19):1881-1882. PMID: 31067395.
    Citations: 25     Fields:    Translation:Humans
  50. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 04 23; 139(17):2022-2031. PMID: 30786725.
    Citations: 155     Fields:    Translation:Humans
  51. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 05 28; 139(22):2516-2527. PMID: 30882239.
    Citations: 70     Fields:    Translation:Humans
  52. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 05 28; 139(22):2528-2536. PMID: 30882238.
    Citations: 146     Fields:    Translation:Humans
  53. Morrow DA, Wiviott SD. Classification of Deaths in Cardiovascular Outcomes Trials. Circulation. 2019 02 12; 139(7):874-876. PMID: 30742536.
    Citations: 3     Fields:    Translation:Humans
  54. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 01 15; 139(3):366-375. PMID: 30586726.
    Citations: 12     Fields:    Translation:Humans
  55. Bohula EA, Wiviott SD, Scirica BM. Lorcaserin Safety in Overweight or Obese Patients. N Engl J Med. 2019 01 03; 380(1):100. PMID: 30601747.
    Citations: 1     Fields:    Translation:Humans
  56. Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Diaz R, Van de Werf F, Corbalán R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. J Am Heart Assoc. 2018 11 20; 7(22):e009260. PMID: 30571502.
    Citations: 5     Fields:    Translation:Humans
  57. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 01 05; 393(10166):31-39. PMID: 30424892.
    Citations: 633     Fields: